logo
Plus   Neg
Share
Email

Amgen's Phase 3 CANDOR Study Meets Primary Endpoint Of PFS - Quick Facts

Amgen (AMGN) said Friday that the Phase 3 CANDOR study evaluating KYPROLIS in combination with dexamethasone and DARZALEX or KdD compared to KYPROLIS and dexamethasone alone met its primary endpoint of progression-free survival.

The regimen resulted in a 37% reduction in the risk of progression or death in patients with relapsed or refractory multiple myeloma treated with KdD.

The CANDOR data will be submitted to a future medical meeting and discussed with health authorities in preparation for regulatory submissions, the company said in a statement.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Justice has reached a settlement agreement with a Texas-based Taco Bell franchise owner for immigration-related discrimination against certain employees. The settlement resolves the DOJ's investigation into whether MUY Brands LLC, and a related management company, MUY Consulting Inc., violated the Immigration and Nationality Act. Starbucks is gearing up for the upcoming holiday season by introducing its 2019 holiday flavors in U.S. grocery stores. The launch of the coffee giant's holiday line-up this year includes returning holiday favorites as well as a new item. Customers can now take home products that are making a comeback such as Starbucks Holiday Blend K-Cup and Ground Coffee, Peppermint Mocha Flavored Ground Coffee, Peekay International issued a recall of 7 ounce and 14 ounce packs containing Keshav Dry Apricot food treats as they contain undeclared allergens such as sulfites, according to a statement published by The U.S. Food and Drug Administration. Consumption of the product by those allergic or having severe sensitivity to sulfites could run the risk of serious or life-threatening allergic reactions.
Follow RTT
>